Alzheimer’s drug Leqembi gets full OK; Biotech’s H1 by the numbers; Bringing Leerink back; Against AI overhype; and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

Long­time read­ers would be fa­mil­iar with our an­nu­al spe­cial re­port hon­or­ing women in bio­phar­ma R&D. This year we’ve moved the pub­li­ca­tion of the pro­files and the ac­com­pa­ny­ing event to Ju­ly. We would love to see you there — you can find more de­tails here.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN